TB-500

TB-500 is a lab-made peptide, a short chain of amino acids copied from one small piece of a natural protein called thymosin beta-4. Sellers and wellness clinics market it for faster healing and recovery. It is not an FDA-approved medicine, and no United States prescribing label exists for it.

That single fact shapes everything else on this page. There is no approved indication to quote, no official dose range, no standard side effect table and no pharmacy monograph. What exists instead is laboratory research, animal studies, a small amount of human research on the parent protein, and a large amount of marketing. This guide separates those layers so you can judge the compound on evidence rather than promise.

What TB-500 is, and what it is not

Thymosin beta-4 is a protein your own cells make. It sits inside cells and helps them move, repair and rebuild after damage. TB-500 is not that whole protein. It is a synthetic seven amino acid fragment, often written as Ac-LKKTETQ, taken from the region of thymosin beta-4 that binds to a cell scaffolding protein called actin.

This matters when you read claims online. Some marketing borrows results from studies on the full thymosin beta-4 molecule, which has been tested in humans for eye surface disease and slow-healing wounds, then applies them to the short fragment sold in vials. The two are related, but they are not the same substance, and results with one do not automatically transfer to the other.

It is also not a hormone and not an anabolic steroid. Steroids are fat-soluble molecules that act on hormone receptors. Peptides are amino acid chains that act on different signalling pathways. Because of that difference, there is no reason to expect this fragment to behave like testosterone or a steroid, and no published human data showing that it does.

If you are used to reading about approved treatments, the contrast is stark. Approved drugs arrive with a label, a warnings section, a list of studied interactions and a known manufacturing standard. Compounds in this category arrive with none of that. Our Medication Reference Index is a useful comparison point, because most entries there carry official labelling that this one simply does not have.

How the peptide is believed to work

The proposed mechanism is straightforward to describe. Actin is part of the internal skeleton of a cell. Cells use it to change shape and crawl toward injured tissue. Laboratory work suggests thymosin beta-4 helps organise actin, which in turn helps cells migrate into a wound bed.

Three other effects are commonly described in preclinical research on the parent protein. It appears to encourage the growth of small new blood vessels, a process called angiogenesis. It appears to dampen some inflammatory signalling. It also appears to reduce fibrosis, meaning the stiff scar tissue that can form after injury. Published research on thymosin beta-4 biology is indexed in the National Library of Medicine database for readers who want the primary papers.

Plausible biology is not the same as proven benefit in people. Many compounds behave beautifully in a dish and in mice, then fail in human trials, or work only at doses that cause harm. A mechanism tells you what to test. It does not tell you what happens to a person with a partly torn tendon who injects a vial bought online.

What the research supports, and where it stops

Most TB-500 marketing rests on animal work. Rodent studies have looked at skin wounds, heart muscle injury, corneal damage and nerve repair, generally using thymosin beta-4 or peptide fragments derived from it. Some of those studies report faster closure or less scarring. They are early-stage findings, not clinical proof.

Human research is thinner than the sales copy suggests. Clinical trials involving thymosin beta-4 preparations have mostly targeted eye surface disease and chronic wounds rather than sports injuries. You can review the trial record yourself through the federal clinical trials registry maintained by the National Institutes of Health. What you will not find is a completed, large, well-controlled human trial showing that the injected fragment repairs tendons, ligaments or muscle faster than standard rehabilitation.

That is also the honest answer to the most common question people ask, which is how quickly it works. There is no established onset, because there is no established effect in humans to time. Timelines quoted in forums and clinic pages come from personal reports, not from measured outcomes, and personal reports cannot separate the compound from rest, physical therapy and normal healing.

Hair growth follows the same pattern. Animal research has linked thymosin beta-4 to hair follicle development, which is why the claim circulates. No human trial has shown that injecting this fragment regrows hair, so treating it as a hair loss treatment goes well beyond the evidence. Our Editorial Coverage looks at how this gap between early research and consumer marketing repeats across the peptide category.

Side effects people report and the blanks that remain

Because the compound has never gone through approval, there is no systematic safety database behind it. Nobody has counted adverse events across thousands of patients, so any frequency figure you see quoted is invented rather than measured.

Effects users commonly describe are mostly local and short-lived. These include injection site pain, redness, itching or a small lump, plus general complaints such as tiredness, headache, flushing, brief lightheadedness and nausea. These reports are anecdotal, and mild symptoms can have many causes.

The unanswered questions carry more weight than the reported ones:

• No long-term human safety data exists, so effects after months or years of use are unknown.
• Because the biology involves new blood vessel growth and cell movement, researchers have raised a theoretical concern for anyone with a current or previous cancer. This is unstudied in people, not proven, and it is a reason for caution rather than reassurance.
• Immune effects are unclear, since thymosin proteins interact with immune signalling.
• Effects in pregnancy, breastfeeding and children have not been studied at all.
• Injecting a product you reconstitute yourself adds infection risk that has nothing to do with the molecule.

Anyone who experiences a reaction after using an unapproved product can report it through the FDA adverse event reporting program known as MedWatch. Reports from consumers are part of how regulators spot patterns.

Warnings, interactions and who should be most cautious

There are no published human drug interaction studies for this fragment. That is a genuine blank, not a formality. With approved medicines, interaction sections exist because researchers dosed people and measured what happened. Here, nobody has.

Practical caution follows from that. If you take blood thinners, immune-suppressing medicines, cancer treatment, or anything with a narrow safety margin, an untested compound adds risk you cannot quantify. Tell any clinician you see what you are using or considering, including the vial label and the source, so they can factor it into decisions. Never stop or delay a prescribed treatment in order to try a peptide.

Two more warnings deserve plain statements. First, products sold as unapproved new drugs have not been shown to be safe or effective, and the FDA describes the wider risks of unapproved drug products marketed in the United States. Second, an injectable product that was never made to pharmaceutical standards can contain the wrong amount of active ingredient, the wrong substance entirely, or bacterial contamination.

Compounded preparations versus research chemicals

Two supply routes dominate. Neither delivers an FDA-approved product, and compounded medicines in general are not reviewed by the FDA for safety, effectiveness or quality before they are sold, even when the active ingredient in some other product is approved.

The two pharmacy categories are worth knowing. A 503A pharmacy compounds for one patient at a time against a prescription. A 503B outsourcing facility registers with the FDA, follows stricter manufacturing rules and can make batches. Both operate outside the approval system that governs ordinary prescriptions.

There is a further hurdle specific to this molecule. The FDA maintains lists of bulk substances nominated for use in compounding, and it has placed thymosin beta-4 in the category of substances that raise significant safety risks, which you can read on the agency page covering bulk drug substances nominated for compounding. In practice, many licensed compounders will not touch it, which pushes demand toward grey-market sellers. If a program tells you it can supply the compound, ask which pharmacy fills it and confirm that pharmacy is licensed in your state. The Telehealth Provider Directory is a starting point for identifying who operates in this space.

TB-500 and BPC-157 side by side

These two are almost always discussed together, and often sold stacked. The honest comparison is short: no head-to-head human trial has compared them, so nobody can say which one is better for a given injury. Anyone who ranks them is ranking marketing claims.

Stacking them multiplies the unknowns rather than the benefits. Two unstudied products taken together give you two unknown safety profiles and no way to tell which one caused a reaction. Our BPC-157 Evidence Overview covers that compound in the same plain terms.

Banned in sport and discouraged for service members

TB-500 is prohibited in tested sport at all times, in and out of competition, and it is detectable on modern anti-doping tests. Athletes should treat it as a sanction risk rather than a grey area, and the governing rules sit in the World Anti-Doping Agency prohibited list. The same logic applies to collegiate and professional programs that follow similar lists.

Military readers face a parallel problem. Peptides marketed for recovery are a recurring theme in supplement safety warnings, partly because products bought online can contain undisclosed ingredients. The Department of Defense runs an official supplement safety resource for service members that addresses this category directly. A positive test or an unexpected ingredient can affect a career, which is a cost no clinic page mentions.

What it costs when you pay cash

There is no standard published cash price for TB-500, and it is not tracked the way approved prescriptions are, because it has no approved form to price. Insurance plans do not cover products that lack FDA approval, so this is a self-pay purchase in almost every case. Verify anything cost-related with your own plan before assuming otherwise.

What actually drives your out-of-pocket total:

• Consultation or membership fee, which can be one-off or recurring monthly.
• Vial size, concentration and how many vials a course is said to require.
• Whether a licensed compounding pharmacy or an unregulated seller is filling it, which changes both price and risk.
• Supplies you buy separately, such as syringes, alcohol wipes and bacteriostatic water.
• Lab work, if a clinician orders it, and shipping.
• Whether an introductory rate later renews at a higher one.

Because peptide protocols are sold as multi-week courses, the monthly figure understates the commitment. Working out the annual total before you start makes the trade-off far clearer.

For contrast, look at a category where prices are tracked and comparable, such as our Semaglutide Cost Basics page. Approved molecules have competing programs, published self-pay figures and a real market. Unapproved peptides have opaque pricing and no reference point, which is exactly why quoted numbers vary so widely. Advertised self-pay prices also change often, so treat any figure you find as a snapshot. If you are budgeting across several treatments, the Sample Savings Report shows the format we use for cash-pay comparisons, and Free Health Calculators can help you model totals.

How telehealth programs handle peptide requests

Programs differ far more here than they do for mainstream prescriptions. Some clinics decline peptides entirely on regulatory grounds. Others build a whole membership around them. Between those poles, the things worth comparing are concrete.

1. Who evaluates you: a licensed physician, a nurse practitioner, or an intake form with no real assessment.
2. Whether the clinician is named and licensed in your state, and whether telemedicine prescribing rules there allow the visit type offered.
3. Whether any injury assessment, imaging review or lab work happens before a product is shipped.
4. Which pharmacy fills the order, and whether that pharmacy is disclosed in writing.
5. What follow-up looks like, including who answers questions about injection technique or a reaction.
6. What the monthly charge actually includes, and how cancellation and refunds work.

The comparison discipline is the same one used for better-established categories. Our Choosing A GLP-1 Program guide walks through those dimensions in detail, and the criteria behind our provider scores are set out in How Scores Are Built. Applied to peptides, the same questions tend to expose which programs are clinical and which are storefronts.

Questions worth asking before you start

• What is the approval status of this exact product, and who made it?
• Is the pharmacy named, licensed and able to provide sterility documentation?
• What evidence supports using it for my specific injury, and is it human evidence?
• What are the realistic alternatives, including physical therapy, imaging or an in-person specialist review?
• How would we know it is not working, and when would we stop?
• Which of my current medicines or conditions could make this a poor idea?
• Am I subject to drug testing at work, in sport or in service?
• What is the total cost of a full course, not the monthly headline?

A clinician who answers these directly is a better sign than one who leads with results. Vague answers about proprietary protocols are a reason to slow down.

When to get medical help

Seek emergency care right away for trouble breathing, swelling of the face, lips or throat, chest pain, fainting, or a severe rash spreading over the body. These can signal a serious allergic reaction.

Contact a clinician promptly for spreading redness, warmth or pus at an injection site, fever or chills, a hard painful lump that keeps growing, or worsening pain in the area you were trying to treat. Infection after self-injection needs treatment, not patience. Any new or unexplained symptom that follows starting an unapproved product is worth reporting to a professional, and worth mentioning even if it seems minor.

Authoritative sources

• The FDA hub explaining how human drug compounding is regulated and what it does not guarantee.
• Plain-language background on supplement and non-drug product safety from MedlinePlus, run by the National Library of Medicine.
• Guidance on registered facilities in the FDA list of 503B outsourcing facilities.

Educational content, not medical advice. Always consult a qualified clinician before starting, stopping or switching treatment.